Published in Biochem Biophys Res Commun on October 11, 2002
Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol (2008) 2.97
Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity (2012) 2.16
Cytotoxic CD4 T cells in antiviral immunity. J Biomed Biotechnol (2011) 1.49
Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells. Blood (2015) 1.43
Granzyme A activates another way to die. Immunol Rev (2010) 1.28
The transcriptional control of the perforin locus. Immunol Rev (2010) 1.15
Epigenetic regulation of NK cell differentiation and effector functions. Front Immunol (2013) 0.96
Evidence for differential alternative splicing in blood of young boys with autism spectrum disorders. Mol Autism (2013) 0.85
Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency. J Exp Med (2014) 0.85
IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential. PLoS One (2014) 0.81
Anti-G-CSF treatment induces protective tumor immunity in mouse colon cancer by promoting protective NK cell, macrophage and T cell responses. Oncotarget (2015) 0.80
Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nat Commun (2016) 0.77
STATs in NK-Cells: The Good, the Bad, and the Ugly. Front Immunol (2017) 0.75
Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol (2003) 6.61
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis (2007) 4.05
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (2004) 3.92
Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol (2008) 1.56
Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption. J Cell Biochem (2010) 1.54
Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol (2007) 1.52
A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol (2006) 1.46
Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum (2005) 1.41
Revised Japanese criteria for Sjögren's syndrome (1999): availability and validity. Mod Rheumatol (2004) 1.40
Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors. J Immunol (2008) 1.34
Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc Natl Acad Sci U S A (2007) 1.32
Reactive oxygen species generated by hematopoietic cytokines play roles in activation of receptor-mediated signaling and in cell cycle progression. Cell Signal (2005) 1.30
SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit. Biochem Biophys Res Commun (2003) 1.27
Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol (2013) 1.24
Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. J Immunol (2009) 1.23
Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol (2007) 1.21
Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis (2013) 1.20
Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis Res Ther (2006) 1.20
Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J Immunol (2004) 1.19
Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther (2009) 1.19
Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum (2002) 1.18
Mammalian twisted gastrulation is essential for skeleto-lymphogenesis. Mol Cell Biol (2003) 1.17
Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J Immunol (2002) 1.16
The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochem Biophys Res Commun (2004) 1.16
Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis (2011) 1.16
Transient receptor potential vanilloid 4 deficiency suppresses unloading-induced bone loss. J Cell Physiol (2008) 1.15
Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol (2009) 1.13
Functional analysis of activating receptor LMIR4 as a counterpart of inhibitory receptor LMIR3. J Biol Chem (2007) 1.12
Diagnosis of intraocular lymphoma by polymerase chain reaction analysis and cytokine profiling of the vitreous fluid. Jpn J Ophthalmol (2009) 1.11
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res (2009) 1.10
Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol (2009) 1.10
Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum (2009) 1.09
A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol (2007) 1.09
Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity (2005) 1.08
Relapsing Campylobacter coli bacteremia with reactive arthritis in a patient with X-linked agammaglobulinemia. Intern Med (2007) 1.06
Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol (2012) 1.06
Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.05
Analysis of mouse LMIR5/CLM-7 as an activating receptor: differential regulation of LMIR5/CLM-7 in mouse versus human cells. Blood (2007) 1.04
Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. Oncogene (2005) 1.04
Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol (2003) 1.04
Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol (2005) 1.02
Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med (2007) 1.01
Pneumatosis cystoides intestinalis following lupus enteritis and peritonitis. Intern Med (2008) 1.01
Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 1.00
BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. Oncogene (2003) 0.99
[Primary multifocal osseous Hodgkin lymphoma]. Rinsho Ketsueki (2009) 0.98
Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL/J mice. J Immunol (2005) 0.98
[Pure red cell aplasia successfully treated with rituximab in a patient with relapsed diffuse large B-cell lymphoma]. Rinsho Ketsueki (2007) 0.98
Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6. Arthritis Rheum (2006) 0.98
IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells. Eur J Cell Biol (2007) 0.97
c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway. J Biol Chem (2011) 0.97
TIMP-3 recruits quiescent hematopoietic stem cells into active cell cycle and expands multipotent progenitor pool. Blood (2010) 0.97
Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Mod Rheumatol (2013) 0.96
Comprehensive analysis of myeloid lineage conversion using mice expressing an inducible form of C/EBP alpha. EMBO J (2006) 0.96
A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. Arthritis Rheum (2007) 0.96
SDF-1 synergistically enhances IL-3-induced activation of the Raf-1/MEK/Erk signaling pathway through activation of Rac and its effector Pak kinases to promote hematopoiesis and chemotaxis. Cell Signal (2005) 0.95
Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells. PLoS Pathog (2011) 0.94
Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. Apoptosis (2010) 0.94
Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthritis Rheum (2009) 0.93
Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum (2009) 0.93
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis (2012) 0.92
A case of paraneoplastic syndrome mimicking adult-onset Still's disease. Mod Rheumatol (2004) 0.92
Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther (2005) 0.92
Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis. Int J Hematol (2011) 0.91
Disease-association analysis of an inflammation-related feedback loop. Cell Rep (2013) 0.91
[Case of subcutaneous and mesenteric acute panniculitis with Sjögren's syndrome]. Nihon Rinsho Meneki Gakkai Kaishi (2002) 0.91
Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis. J Immunol (2003) 0.91
miR-31 controls osteoclast formation and bone resorption by targeting RhoA. Arthritis Res Ther (2013) 0.91
Infected abdominal aortic aneurysm caused by nontyphoid Salmonella in an immunocompromised patient with rheumatoid arthritis. J Infect Chemother (2009) 0.91
Pulmonary exercise testing predicts prognosis in patients with chronic obstructive pulmonary disease. Intern Med (2005) 0.91
Fusion of MLL and MSF in adult de novo acute myelomonocytic leukemia (M4) with t(11;17)(q23;q25). Int J Hematol (2002) 0.90
Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Cancer Genet Cytogenet (2005) 0.90
Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheumatol (2013) 0.90
Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol (2012) 0.89
Necessity of lysophosphatidic acid receptor 1 for development of arthritis. Arthritis Rheum (2013) 0.89
Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis. Arthritis Res Ther (2011) 0.89
ASK1 is activated by arsenic trioxide in leukemic cells through accumulation of reactive oxygen species and may play a negative role in induction of apoptosis. Biochem Biophys Res Commun (2007) 0.88
Activation of CCAAT/enhancer-binding protein alpha or PU.1 in hematopoietic stem cells leads to their reduced self-renewal and proliferation. Stem Cells (2008) 0.88
BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells. Biochem Biophys Res Commun (2005) 0.88
DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3β. PLoS One (2011) 0.88
Role for protein geranylgeranylation in adult T-cell leukemia cell survival. Exp Cell Res (2008) 0.87
Pathogenic role of CXCR7 in rheumatoid arthritis. Arthritis Rheum (2010) 0.87
Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br J Haematol (2015) 0.87
Cloning and characterization of the human BAZF gene, a homologue of the BCL6 oncogene. Biochem Biophys Res Commun (2002) 0.87
Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology (Oxford) (2014) 0.87
Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanese population with a high childhood incidence of asymptomatic primary EBV infection. Clin Diagn Lab Immunol (2004) 0.86
[A case report of hypertrophic pachymeningitis associated with systemic lupus erythematosus, showing a headache and hearing loss resembling intracranial hypotension]. Nihon Rinsho Meneki Gakkai Kaishi (2007) 0.86
p16(INK4a) exerts an anti-inflammatory effect through accelerated IRAK1 degradation in macrophages. J Immunol (2012) 0.86
N-terminal region of CCAAT/enhancer-binding protein epsilon is critical for cell cycle arrest, apoptosis, and functional maturation during myeloid differentiation. J Biol Chem (2006) 0.86
Outcomes of endoscopic submucosal dissection for early gastric cancer and factors associated with incomplete resection. Hepatogastroenterology (2013) 0.86
Cognitive dysfunction in systemic lupus erythematosus. Psychiatry Clin Neurosci (2005) 0.85